Product Code: VMR11215654
Cell & gene therapy manufacturing services include comprehensive and seamless manufacturing and quality-testing services for cellular and gene therapy products. The service provider helps biotechnology & pharmaceutical companies and research groups boost translational and clinical discoveries and foster an environment of collaboration and innovation. Cell therapy manufacturing services include allogeneic, autologous, and viral vectors, while gene therapy manufacturing services non-viral vectors, oligonucleotides, and viral vectors. Cell & gene therapy manufacturing services provide flexible and pioneering tools to simplify workflow, innovation, scalability, customization, consistency, reproducibility, reducing risk, and navigate at every step of the manufacturing process.
Market Dynamics:
Factors such as the high prevalence of cancer and chronic diseases, increasing spending in pharmaceutical & biological research, and increasing collaboration among companies and CDMOs are primarily driving the growth of the global cell & gene therapy manufacturing services market. Cell and gene therapies offer potential promise to treat and relieve life-threatening diseases. Pharmaceutical companies are massively investing in the development of new drugs and therapies. Pharmaceutical companies are more usually outsource their research CDMOs or CROs to focus on core activities. Moreover, Pharmaceutical companies find it challenging to do R&D with high quality and efficiency. Outsourcing stands out as the best approach to them. However, the high operational costs concerned with cell & gene therapy manufacturing are likely to restrain market growth to some extent.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell & gene therapy manufacturing services. The growth and trends of cell & gene therapy manufacturing services industry provide a holistic approach to this study.
Market Segmentation:
This section of the cell & gene therapy manufacturing services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Cell Therapy (Allogeneic, Autologous, Viral Vector)
- Gene Therapy (Non-viral Vector, Viral Vector)
By Indication
- Oncology Diseases
- Cardiovascular Diseases
- Orthopedic Diseases
- Ophthalmology Diseases
- Central Nervous System Disorders
- Infectious Diseases
- Other
By Application
- Clinical Manufacturing
- Commercial Manufacturing
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Other End User
Regional Analysis:
This section covers the regional outlook, which accentuates current and future demand for the Cell & Gene Therapy Manufacturing Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell & gene therapy manufacturing services market include Lonza (Switzerland), Catalent Inc. (US), Thermo Fisher Scientific Inc. (US), Charles River Laboratories (US), WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Cell and Gene Therapy Catapult (UK), Genezen (US), FUJIFILM Holdings Corporation (Japan), Nikon Corporation (Japan), The Discovery Labs LLC (US), RoslinCT (Scotland), JRS Pharma (Germany), FinVector (Finland), ABL Inc. (US), Resilience (US), BioCentriq (US), Porton Advanced Solutions (China), Andelyn Biosciences (US), Forge Biologics (US), Vibalogics (US), Anemocyte Srl (Italy), ElevateBio (US) This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
- In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . CELL & GENE THERAPY MANUFACTURING SERVICES - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 By Type
- 3.7.2 By Indication
- 3.7.3 By Application
- 3.7.4 By End User
- 3.7.5 By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
6 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY TYPE
- 6.1 Overview by Type
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Type
- 6.4 Cell Therapy Market by Regions
- 6.5 Gene Therapy Market by Regions
7 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY INDICATION
- 7.1 Overview by Indication
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Indication
- 7.4 Oncology Diseases Market by Regions
- 7.5 Cardiovascular Diseases Market by Regions
- 7.6 Orthopedic Diseases Market by Regions
- 7.7 Ophthalmology Diseases Market by Regions
- 7.8 Central Nervous System Disorders Market by Regions
- 7.9 Infectious Diseases Market by Regions
- 7.10. Other Market by Regions
8 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY APPLICATION
- 8.1 Overview by Application
- 8.2 Historical and Forecast Data
- 8.3 Analysis by Application
- 8.4 Clinical Manufacturing Market by Regions
- 8.5 Commercial Manufacturing Market by Regions
9 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY END USER
- 9.1 Overview by End User
- 9.2 Historical and Forecast Data
- 9.3 Analysis by End User
- 9.4 Pharmaceutical & Biotechnology Companies Market by Regions
- 9.5 Academic & Research Institutes Market by Regions
- 9.6 Other End User Market by Regions
10 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America
- 10.3.1. Overview, Historic and Forecast Data
- 10.3.2. North America By Segment
- 10.3.3. North America By Country
- 10.3.4. United State
- 10.3.5. Canada
- 10.3.6. Mexico
- 10.4. Europe
- 10.4.1. Overview, Historic and Forecast Data
- 10.4.2. Europe by Segment
- 10.4.3. Europe by Country
- 10.4.4. United Kingdom
- 10.4.5. France
- 10.4.6. Germany
- 10.4.7. Italy
- 10.4.8. Russia
- 10.4.9. Rest Of Europe
- 10.5. Asia Pacific
- 10.5.1. Overview, Historic and Forecast Data
- 10.5.2. Asia Pacific by Segment
- 10.5.3. Asia Pacific by Country
- 10.5.4. China
- 10.5.5. India
- 10.5.6. Japan
- 10.5.7. South Korea
- 10.5.8. Australia
- 10.5.9. Rest Of Asia Pacific
- 10.6. Latin America
- 10.6.1. Overview, Historic and Forecast Data
- 10.6.2. Latin America by Segment
- 10.6.3. Latin America by Country
- 10.6.4. Brazil
- 10.6.5. Argentina
- 10.6.6. Peru
- 10.6.7. Chile
- 10.6.8. Rest of Latin America
- 10.7. Middle East & Africa
- 10.7.1. Overview, Historic and Forecast Data
- 10.7.2. Middle East & Africa by Segment
- 10.7.3. Middle East & Africa by Country
- 10.7.4. Saudi Arabia
- 10.7.5. UAE
- 10.7.6. Israel
- 10.7.7. South Africa
- 10.7.8. Rest Of Middle East And Africa
11 . COMPETITIVE LANDSCAPE OF THE CELL & GENE THERAPY MANUFACTURING SERVICES COMPANIES
- 11.1. Cell & Gene Therapy Manufacturing Services Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12 . COMPANY PROFILES OF CELL & GENE THERAPY MANUFACTURING SERVICES INDUSTRY
- 12.1. Company Share Analysis
- 12.2. Market Concentration Rate
- 12.3. Lonza (Switzerland)
- 12.3.1. Company Overview
- 12.3.2. Financials
- 12.3.3. Products
- 12.3.4. Recent Developments
- 12.4. Catalent Inc. (US)
- 12.4.1. Company Overview
- 12.4.2. Financials
- 12.4.3. Products
- 12.4.4. Recent Developments
- 12.5. Thermo Fisher Scientific Inc. (US)
- 12.5.1. Company Overview
- 12.5.2. Financials
- 12.5.3. Products
- 12.5.4. Recent Developments
- 12.6. Charles River Laboratories (US)
- 12.6.1. Company Overview
- 12.6.2. Financials
- 12.6.3. Products
- 12.6.4. Recent Developments
- 12.7. WuXi AppTec (China)
- 12.7.1. Company Overview
- 12.7.2. Financials
- 12.7.3. Products
- 12.7.4. Recent Developments
- 12.8. Merck KGaA (Germany)
- 12.8.1. Company Overview
- 12.8.2. Financials
- 12.8.3. Products
- 12.8.4. Recent Developments
- 12.9. Takara Bio Inc. (Japan)
- 12.9.1. Company Overview
- 12.9.2. Financials
- 12.9.3. Products
- 12.9.4. Recent Developments
- 12.10. Oxford Biomedica (UK)
- 12.10.1. Company Overview
- 12.10.2. Financials
- 12.10.3. Products
- 12.10.4. Recent Developments
- 12.11. Cell and Gene Therapy Catapult (UK)
- 12.11.1. Company Overview
- 12.11.2. Financials
- 12.11.3. Products
- 12.11.4. Recent Developments
- 12.12. Genezen (US)
- 12.12.1. Company Overview
- 12.12.2. Financials
- 12.12.3. Products
- 12.12.4. Recent Developments
- 12.13. FUJIFILM Holdings Corporation (Japan)
- 12.13.1. Company Overview
- 12.13.2. Financials
- 12.13.3. Products
- 12.13.4. Recent Developments
- 12.14. Nikon Corporation (Japan)
- 12.14.1. Company Overview
- 12.14.2. Financials
- 12.14.3. Products
- 12.14.4. Recent Developments
- 12.15. The Discovery Labs LLC (US)
- 12.15.1. Company Overview
- 12.15.2. Financials
- 12.15.3. Products
- 12.15.4. Recent Developments
- 12.16. RoslinCT (Scotland)
- 12.16.1. Company Overview
- 12.16.2. Financials
- 12.16.3. Products
- 12.16.4. Recent Developments
- 12.17. JRS Pharma (Germany)
- 12.17.1. Company Overview
- 12.17.2. Financials
- 12.17.3. Products
- 12.17.4. Recent Developments
- 12.18. FinVector (Finland)
- 12.18.1. Company Overview
- 12.18.2. Financials
- 12.18.3. Products
- 12.18.4. Recent Developments
- 12.19. ABL Inc. (US)
- 12.19.1. Company Overview
- 12.19.2. Financials
- 12.19.3. Products
- 12.19.4. Recent Developments
- 12.20. Resilience (US)
- 12.20.1. Company Overview
- 12.20.2. Financials
- 12.20.3. Products
- 12.20.4. Recent Developments
- 12.21. BioCentriq (US)
- 12.21.1. Company Overview
- 12.21.2. Financials
- 12.21.3. Products
- 12.21.4. Recent Developments
- 12.22. Porton Advanced Solutions (China)
- 12.22.1. Company Overview
- 12.22.2. Financials
- 12.22.3. Products
- 12.22.4. Recent Developments
- 12.23. Andelyn Biosciences (US)
- 12.23.1. Company Overview
- 12.23.2. Financials
- 12.23.3. Products
- 12.23.4. Recent Developments
- 12.24. Forge Biologics (US)
- 12.24.1. Company Overview
- 12.24.2. Financials
- 12.24.3. Products
- 12.24.4. Recent Developments
- 12.25. Vibalogics (US)
- 12.25.1. Company Overview
- 12.25.2. Financials
- 12.25.3. Products
- 12.25.4. Recent Developments
- 12.26. Anemocyte Srl (Italy)
- 12.26.1. Company Overview
- 12.26.2. Financials
- 12.26.3. Products
- 12.26.4. Recent Developments
- 12.27. ElevateBio (US)
- 12.27.1. Company Overview
- 12.27.2. Financials
- 12.27.3. Products
- 12.27.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies